{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T13:09:37Z","timestamp":1772456977482,"version":"3.50.1"},"reference-count":48,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T00:00:00Z","timestamp":1686873600000},"content-version":"unspecified","delay-in-days":15,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011725","name":"Servier","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100011725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open Diab Res Care"],"accepted":{"date-parts":[[2023,5,23]]},"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Most data demonstrating the efficacy and safety of luseogliflozin (luseo) in people with type 2 diabetes mellitus (T2DM) originate from the Japanese population. This study evaluated luseo versus placebo (PCB) as add-on to metformin in a Caucasian population with inadequately controlled T2DM.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Research design and methods<\/jats:title>\n                  <jats:p>This was a multicenter, randomized, double-blind, PCB-controlled, parallel-group study. Patients aged 18\u201375 years with inadequately controlled T2DM (glycated hemoglobin (HbA1c) \u22657% to \u226410% (\u226553 to \u226486 mmol\/mol)) despite a diet and exercise program and on a stable metformin regimen were eligible. Patients were randomized to one of three luseo groups (2.5, 5.0 and 10.0 mg) or PCB for 12 weeks (W12). The primary endpoint was change in HbA1c expressed as least-square means from baseline (W0) to W12.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 328 patients were randomized: PCB (n=83) and luseo 2.5 mg (n=80), 5.0 mg (n=86), and 10.0 mg (n=79). Mean age (\u00b1SD) was 58.5\u00b18.8 years; 64.6% were women; body mass index was 31.5\u00b13.4 kg\/m<jats:sup>2<\/jats:sup>; and HbA1c was 8.54\u00b10.70. At W12, mean reductions in HbA1c from W0 were \u22120.98%, \u22121.09%, \u22121.18%, and \u22120.73% in the luseo 2.5, 5.0 and 10.0 mg, and PCB groups, respectively, all of which were statistically significant. Compared with PCB, HbA1c levels were significantly decreased by 0.25% (p=0.045), 0.36% (p=0.006), and 0.45% (p=0.001) in the luseo 2.5, 5.0, and 10.0 mg groups, respectively. In all luseo dose groups, reductions in body weight were statistically significant compared with PCB. Data from the safety analysis were consistent with the known luseo safety profile.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>All doses of luseo as add-on to metformin in Caucasian patients with uncontrolled T2DM demonstrated significant efficacy in decreasing HbA1c after W12 of treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Trial registration number<\/jats:title>\n                  <jats:p>\n                     <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"isrctn\" xlink:href=\"ISRCTN39549850\">ISRCTN39549850<\/jats:ext-link>.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjdrc-2022-003290","type":"journal-article","created":{"date-parts":[[2023,6,16]],"date-time":"2023-06-16T13:30:42Z","timestamp":1686922242000},"page":"e003290","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Efficacy and safety of luseogliflozin in Caucasian patients with type 2 diabetes: results from a phase III, randomized, placebo-controlled, clinical trial"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"isrctn39549850","registry":"10.18810\/isrctn"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5057-127X","authenticated-orcid":false,"given":"Marina","family":"Shestakova","sequence":"first","affiliation":[{"name":"Endocrinology Research Center, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0806-7061","authenticated-orcid":false,"given":"Boris","family":"Kvasnikov","sequence":"additional","affiliation":[{"name":"Medical Affairs, Servier JSC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-0815","authenticated-orcid":false,"given":"Ekaterina","family":"Erina","sequence":"additional","affiliation":[{"name":"Medical Affairs, Servier JSC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7031-8618","authenticated-orcid":false,"given":"Elena","family":"Isachenko","sequence":"additional","affiliation":[{"name":"Medical Affairs, Servier JSC, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6503-2359","authenticated-orcid":false,"given":"Alexander","family":"Andreev","sequence":"additional","affiliation":[{"name":"Cardiology and functional&ultrasound diagnostics department, First Moscow State Medical University, Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,6,16]]},"reference":[{"key":"2025073112073693000_11.3.e003290.1","unstructured":"IDF diabetes Atlas, 9th ed. Available: http:\/\/www.idf.org\/diabetesatlas\/ [Accessed 12 Jan 2022]."},{"key":"2025073112073693000_11.3.e003290.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2025073112073693000_11.3.e003290.3","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0033"},{"key":"2025073112073693000_11.3.e003290.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)07019-6"},{"key":"2025073112073693000_11.3.e003290.5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7258.412"},{"key":"2025073112073693000_11.3.e003290.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0806470"},{"key":"2025073112073693000_11.3.e003290.7","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2439"},{"key":"2025073112073693000_11.3.e003290.8","doi-asserted-by":"publisher","DOI":"10.2337\/dc21-S006"},{"key":"2025073112073693000_11.3.e003290.9","doi-asserted-by":"publisher","DOI":"10.2337\/dci18-0018"},{"key":"2025073112073693000_11.3.e003290.10","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-041846","article-title":"Trends in known and undiagnosed diabetes, Hba1C levels, cardiometabolic risk factors and diabetes treatment target achievement in repeated cross-sectional surveys: the population-based Troms\u00f8 study 1994-2016","volume":"11","author":"Langholz","year":"2021","journal-title":"BMJ Open"},{"key":"2025073112073693000_11.3.e003290.11","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.amjcard.2019.05.035","article-title":"Control of cardiovascular risk factors among US adults with type 2 diabetes with and without cardiovascular disease","volume":"124","author":"Andary","year":"2019","journal-title":"Am J Cardiol"},{"key":"2025073112073693000_11.3.e003290.12","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00125-019-05078-3","article-title":"Persistent poor Glycaemic control in individuals with type 2 diabetes in developing countries: 12 years of real-world evidence of the International diabetes management practices study (IDMPS)","volume":"63","author":"Aschner","year":"2020","journal-title":"Diabetologia"},{"key":"2025073112073693000_11.3.e003290.13","doi-asserted-by":"crossref","first-page":"204","DOI":"10.14341\/DM12759","article-title":"Epidemiological characteristics of diabetes mellitus in the Russian Federation: clinical and statistical analysis according to the Federal diabetes register data of 01.01.2021","volume":"24","author":"Dedov","year":"2021","journal-title":"Diabetes Mellitus"},{"key":"2025073112073693000_11.3.e003290.14","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2008.12.031"},{"key":"2025073112073693000_11.3.e003290.15","doi-asserted-by":"publisher","DOI":"10.3109\/07853890.2011.560181"},{"key":"2025073112073693000_11.3.e003290.16","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-154-9-201105030-00336"},{"key":"2025073112073693000_11.3.e003290.17","doi-asserted-by":"publisher","DOI":"10.1177\/2042018814553965"},{"key":"2025073112073693000_11.3.e003290.18","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2011.01340.x"},{"key":"2025073112073693000_11.3.e003290.19","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/5584_2020_479","article-title":"Glucose lowering efficacy and pleiotropic effects of sodium-glucose cotransporter 2 inhibitors","volume":"1307","author":"Kuchay","year":"2021","journal-title":"Adv Exp Med Biol"},{"key":"2025073112073693000_11.3.e003290.20","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1185\/03007995.2014.912983","article-title":"Efficacy and safety of Luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025073112073693000_11.3.e003290.21","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1507\/endocrj.EJ15-0097","article-title":"Fifty-two-week long-term clinical study of Luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise","volume":"62","author":"Seino","year":"2015","journal-title":"Endocr J"},{"key":"2025073112073693000_11.3.e003290.22","doi-asserted-by":"crossref","first-page":"2741","DOI":"10.1517\/14656566.2014.978290","article-title":"Luseogliflozin for the treatment of type 2 diabetes","volume":"15","author":"Seino","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"2025073112073693000_11.3.e003290.23","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/jdi.12316","article-title":"Efficacy and safety of Luseogliflozin added to various oral antidiabetic drugs in Japanese patients with type 2 diabetes mellitus","volume":"6","author":"Seino","year":"2015","journal-title":"J Diabetes Investig"},{"key":"2025073112073693000_11.3.e003290.24","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/jdi.12694","article-title":"Sodium-glucose cotransporter-2 inhibitor Luseogliflozin added to glucagon-like peptide 1 receptor agonist Liraglutide improves glycemic control with bodyweight and fat mass reductions in Japanese patients with type 2 diabetes: a 52-week, open-label, single-arm study","volume":"9","author":"Seino","year":"2018","journal-title":"J Diabetes Investig"},{"key":"2025073112073693000_11.3.e003290.25","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.clinthera.2016.01.017","article-title":"Efficacy and safety of the SGLT2 inhibitor Luseogliflozin in Japanese patients with type 2 diabetes mellitus stratified according to baseline body mass index: pooled analysis of data from 52-week phase III trials","volume":"38","author":"Sakai","year":"2016","journal-title":"Clin Ther"},{"key":"2025073112073693000_11.3.e003290.26","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1080\/03007995.2018.1441816","article-title":"Efficacy and safety of Luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period","volume":"34","author":"Seino","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"2025073112073693000_11.3.e003290.27","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1185\/03007995.2014.909390","article-title":"Dose-finding study of Luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study","volume":"30","author":"Seino","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"2025073112073693000_11.3.e003290.28","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.2147\/DMSO.S193528","article-title":"SGLT2 inhibitors as add-on therapy to metformin for people with type 2 diabetes: a review of placebo-controlled trials in Asian versus non-Asian patients","volume":"13","author":"Scheen","year":"2020","journal-title":"Diabetes Metab Syndr Obes"},{"key":"2025073112073693000_11.3.e003290.29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all\u2010cause mortality between Asian and non\u2010Asian type 2 diabetes patients with Sodium\u2010Glucose cotransporter 2 inhibitors treatment: a meta\u2010analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J Diabetes Investig"},{"key":"2025073112073693000_11.3.e003290.30","doi-asserted-by":"crossref","first-page":"263","DOI":"10.3803\/EnM.2015.30.3.263","article-title":"Diabetes in Asians","volume":"30","author":"Rhee","year":"2015","journal-title":"Endocrinol Metab"},{"key":"2025073112073693000_11.3.e003290.31","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.61"},{"key":"2025073112073693000_11.3.e003290.32","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.2217\/pgs.13.171","article-title":"Clinical impact of genetic variants of drug transporters in different ethnic groups within and across regions","volume":"14","author":"Ono","year":"2013","journal-title":"Pharmacogenomics"},{"key":"2025073112073693000_11.3.e003290.33","doi-asserted-by":"publisher","DOI":"10.1159\/000348741"},{"key":"2025073112073693000_11.3.e003290.34","doi-asserted-by":"crossref","first-page":"12748","DOI":"10.18632\/aging.202945","article-title":"The different hypoglycemic effects between East Asian and non-Asian type 2 diabetes patients when treated with SGLT-2 inhibitors as an add-on treatment for metformin: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Li","year":"2021","journal-title":"Aging (Albany NY)"},{"key":"2025073112073693000_11.3.e003290.35","article-title":"Luseogliflozin (TS-071), a novel, potent, and selective inhibitor of Sglt2 is safe and well-tolerated in type 2 diabetes mellitus and showed dose-dependent PK\/KD in both US\/Japanese Ethnicities","volume":"55","author":"Morrow","year":"2012","journal-title":"Diabetologia"},{"key":"2025073112073693000_11.3.e003290.36","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdi.12760","article-title":"No disparity of the efficacy and all\u2010cause mortality between Asian and Non\u2010Asian type 2 diabetes patients with sodium-glucose cotransporter 2 inhibitors treatment: a meta-analysis","volume":"9","author":"Cai","year":"2018","journal-title":"J Diabetes Investig"},{"key":"2025073112073693000_11.3.e003290.37","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2404-1"},{"key":"2025073112073693000_11.3.e003290.38","first-page":"478","article-title":"Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis","volume":"63","author":"Zhang","year":"2019","journal-title":"Arch Endocrinol Metab"},{"key":"2025073112073693000_11.3.e003290.39","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.diabres.2018.10.018","article-title":"A phase 3 randomized placebo-controlled trial to assess the efficacy and safety of Ipragliflozin as an add-on therapy to metformin in Russian patients with inadequately controlled type 2 diabetes mellitus","volume":"146","author":"Shestakova","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073112073693000_11.3.e003290.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2013.08.015"},{"key":"2025073112073693000_11.3.e003290.41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.diabres.2017.07.025","article-title":"Systematic review of metformin monotherapy and dual therapy with sodium glucose co-transporter 2 inhibitor (SGLT-2) in treatment of type 2 diabetes mellitus","volume":"132","author":"Molugulu","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"2025073112073693000_11.3.e003290.42","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8010045","article-title":"Combination therapy with an SGLT2 inhibitor as initial treatment for type 2 diabetes: a systematic review and meta-analysis","volume":"8","author":"Milder","year":"2019","journal-title":"J Clin Med"},{"key":"2025073112073693000_11.3.e003290.43","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1002\/oby.22066","article-title":"The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis","volume":"26","author":"Cai","year":"2018","journal-title":"Obesity (Silver Spring)"},{"key":"2025073112073693000_11.3.e003290.44","unstructured":"World Health Organization . Obesity and overweight fact sheet. 2021. Available: http:\/\/www.who.int\/mediacentre\/factsheets\/fs311\/en [Accessed 09 Feb 2022]."},{"key":"2025073112073693000_11.3.e003290.45","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-014-0337-y"},{"key":"2025073112073693000_11.3.e003290.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.04.012"},{"key":"2025073112073693000_11.3.e003290.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdiacomp.2013.05.004"},{"key":"2025073112073693000_11.3.e003290.48","unstructured":"Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus. n.d. Available: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-clinical-investigation-medicinal-products-treatment-prevention-diabetes-mellitus-revision_en.pdf"}],"container-title":["BMJ Open Diabetes Research &amp; Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjdrc-2022-003290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T19:07:46Z","timestamp":1753988866000},"score":1,"resource":{"primary":{"URL":"https:\/\/drc.bmj.com\/lookup\/doi\/10.1136\/bmjdrc-2022-003290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":48,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,6,16]]},"published-print":{"date-parts":[[2023,6]]}},"alternative-id":["10.1136\/bmjdrc-2022-003290"],"URL":"https:\/\/doi.org\/10.1136\/bmjdrc-2022-003290","relation":{},"ISSN":["2052-4897"],"issn-type":[{"value":"2052-4897","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6]]}}}